Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/7577
Title: The effect of gradual increment in rhG-CSF dose on stem cell yields in patients with multiple myeloma mobilized with intermediate dose cyclophosphamide plus rhG-CSF
Authors: Hacıoglu, Sibel
Sarı, Hakan İsmail
Dogu, M.H.
Keskin, Ali
Keywords: Cyclophosphamide
Granulocyte colony stimulating factor
Multiple myeloma
Stem cell mobilization
antineoplastic agent
cyclophosphamide
mesna
recombinant granulocyte colony stimulating factor
CD34 antigen
granulocyte colony stimulating factor
recombinant protein
adult
aged
apheresis
article
cancer chemotherapy
cancer radiotherapy
chronotherapy
clinical article
drug dose increase
female
hemorrhagic cystitis
human
male
middle aged
multiple myeloma
peripheral blood stem cell
retrospective study
stem cell mobilization
cost benefit analysis
economics
metabolism
procedures
time
Adult
Aged
Antigens, CD34
Blood Component Removal
Cost-Benefit Analysis
Female
Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cell Mobilization
Humans
Male
Middle Aged
Multiple Myeloma
Recombinant Proteins
Retrospective Studies
Time Factors
Publisher: Elsevier Ltd
Abstract: Cyclophosphamide along with recombinant human granulocyte-colony stimulating factor (rhG-CSF) is a commonly used strategy for mobilization. However, the optimal timing for rhG-CSF initiation after cyclophosphamide has not been determined as conclusively as has the G-CSF dose. In this paper, we aimed to present gradual dose increment of rhG-CSF between the third day of mobilization and time to apheresis that is started with 5µg/kg (from day 3 to day 7) and continued with 10µg/kg (from day 8 to time to apheresis) for peripheral blood stem cell (PBSC) mobilization in multiple myeloma (MM) patients and its effect on stem cell yield and mobilization success. Data from 30 consecutive patients with MM who underwent PBSC mobilization between October 2011 and June 2013, were retrospectively reviewed. While twenty-eight of 30 patients (93.3%) were successfully mobilized, 2 patients (6.7%) had mobilization failure. The final median CD34+ cell dose harvested from the patients was 9.5×106/kg. The median number of apheresis was 2.5 (range, 0-3). Twenty-four patients (80%) yielded >2×106 CD34+ cells/kg in one apheresis procedure. In conclusion, our regimen might be used to decrease the mobilization failure regarding the low dose rhG-CSF use and provide a cost effective strategy. © 2013 Elsevier Ltd.
URI: https://hdl.handle.net/11499/7577
https://doi.org/10.1016/j.transci.2013.11.003
ISSN: 1473-0502
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

2
checked on Dec 14, 2024

Page view(s)

68
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.